Mutations of immune system found in breast cancers

November 18, 2013

Mutations in the genes that defend the body against cancer-related viruses and other infections may play a larger role in breast cancer than previously thought, according to a study at the University of Illinois at Chicago.

Bernard Friedenson, associate professor of biochemistry and molecular genetics at UIC, looked at the DNA sequences of breast cancers from 21 different women and found mutations in genes involved in immunity in every one of them. The mutations were different in each of the breast cancers he analyzed, but all the mutations would have affected some aspect of pathogen recognition and defense, especially against viruses, Friedenson said.

His results are published in the November issue of Functional & Integrative Genomics.

The finding suggests that mutations affecting the immune system play an important role in the development of breast cancer, contrary to the prevailing notion that mutations in the genes that regulate cell division are primarily responsible. Viruses such as human papilloma virus, which can cause cervical cancer, and Epstein-Barr virus, which can cause certain lymphomas, have also been implicated in breast cancer.

"Almost every human being is infected with one or more of these viruses, but most people never develop symptoms, much less breast cancer," Friedenson said.

Friedenson thinks that cancer-related viruses that are normally harmless can become dangerous if genes involved in immunity are mutated, either through heredity or environmental causes.

He identified gene mutations in breast cancer cells that affect their ability to recognize viruses, including some mutations that would be expected to significantly increase the cells' vulnerability to viruses implicated in breast cancer.

"If we know which genes are damaged in a breast cancer patient's immune system, prevention or even therapy can be tailored by giving vaccines or perhaps antiviral drugs to reduce the chances of recurrence," said Friedenson. "Sequencing the genomes of individual breast cancers now costs about $2,000, and the cost continues to fall. This information could help physicians prescribe more targeted and effective treatments."

Since 1994, many thousands of women with breast cancer from families severely affected with the disease have been tested for inherited mutations in BRCA1 and BRCA2. The vast majority of those patients were told that their ...

(HealthDay)—Lymph node metastases are more common in breast cancers with mutations in a cellular signaling pathway associated with growth, according to a study published online July 24 in JAMA Surgery.

A major study conducted at the Sahlgrenska Academy has now disproved theories of a viral cause for breast cancer and the brain tumour, glioblastoma. The study, which was based on over seven billion DNA sequences and which ...

Researchers at the University of Minnesota have uncovered a human enzyme responsible for causing DNA mutations found in the majority of breast cancers. The discovery of this enzyme – called APOBEC3B – may change the way ...

(Medical Xpress)—Two teams of researchers, both made up of members from a wide variety of research institutions in the U.S. have independently come up with the same findings: a gene mutation in ESR1 (a gene that encodes ...

Recommended for you

An international team of researchers involving the University of Adelaide is tackling the controversy over what some scientists consider to be a "harmful" hormone, arguing that it could be a game changer in the fight against ...

Breast cancer cells break away and spread to other parts of the body relatively late on in breast tumour development, an international team of scientists has shown. The research, jointly led by Dr Peter Van Loo at the Francis ...

Discovered in the 1970s, tumor suppressors are among the most important proteins in the body. A master regulator of growth—"the guardian of the genome"—the p53 protein monitors cell growth for errors. We rely on suppressors ...

Starting in 1993 and ending in 2001, ten academic medical centers in the United States screened 76,685 men and 78,216 women for prostate, lung, colorectal and ovarian cancers. The question was whether yearly screening could ...

People with head and neck cancers with evidence of human papillomavirus (HPV) infection generally have a better prognosis than people without evidence of infection. A new study in JAMA Oncology suggests that to produce a ...